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Therapeutic Depletion of Natural Killer Cells Controls Persistent
Infection
Stephen N. Waggoner,a,b Keith A. Daniels,a Raymond M. Welsha,b
Department of Pathologya and Program for Immunology and Virology,b University of Massachusetts Medical School, Worcester, Massachusetts, USA
ABSTRACT
Persistent viral infections are associated with host and viral factors that impair effective antiviral immunity. Natural killer (NK)
cells contribute to establishment of persistent lymphocytic choriomeningitis virus (LCMV) infection in mice through suppres-
sion of virus-specific T cell responses during the first few days of infection, but NK cell depletion during those early time points
can enable severe T cell-mediated immune pathology and death of the host. Here we show that long after their peak in cytolytic
activation, NK cells continue to support viral persistence at later times of infection. Delayed depletion of NK cells, 2 to 3 weeks
after infection, enhanced virus-specific T cell responses and viral control. This enhancing effect of delayed NK cell depletion on
antiviral immunity, in contrast to early NK cell depletion, was not associated with increased morbidity andmortality, andmice
quickly regained weight after treatment. The efficacy of the depletion depended in part upon the size of the original virus inocu-
lum, the viral load at the time of depletion, and the presence of CD4 T cells. Each of these factors is an important contributor to
the degree of CD8 T cell dysfunction during viral persistence. Thus, NK cells may continuously contribute to exhaustion of vi-
rus-specific T cells during chronic infection, possibly by depleting CD4 T cells. Targeting of NK cells could thus be considered in
combination with blockade of other immunosuppressive pathways, such as the interleukin-10 (IL-10) and programmed death 1
(PD-1) pathways, as a therapy to cure chronic human infections, including those with HIV or hepatitis C virus.
IMPORTANCE
Persistent virus infections are a major threat to global human health. The capacity of viruses, including HIV and hepatitis C vi-
rus, to overwhelm or subvert host immune responses contributes to a prolonged state of dampened antiviral immune function-
ality, which in turn facilitates viral persistence. Recent efforts have focused on therapeutics that can restore the effector func-
tions of these functionally exhausted virus-specific T cells in order to expedite viral clearance. Here we establish that natural
killer (NK) cells actively contribute to immune dysfunction and viral persistence at later stages of infection. This previously un-
described mechanism of immune suppression during chronic infection provides a vital clue for the design of novel therapeutic
strategies targeting NK cell immunosuppressive activity in order to restore immune function and enhance viral control in chron-
ically infected individuals.
Persistent infections with HIV, hepatitis B virus (HBV), andhepatitis C virus (HCV) are major threats to human health. A
number of host and viral mechanisms cooperate to suppress ef-
fective antiviral immunity and facilitate viral persistence during
these types of infections. An important focus of ongoing research
concerns the targeting of specific host immunosuppressive factors
in order to reinvigorate the immune response. In murine models
of persistent lymphocytic choriomeningitis virus (LCMV) infec-
tion, the blockade of interleukin-10 (IL-10) (1, 2) or programmed
death 1 (PD-1) (3) signaling can enhance LCMV-specific T cell
responses and enable improved control of virus infection. In large
part, thesemechanismsmay have evolved to protect the host from
an overexuberant immune response, as evidenced by the severe
immunopathological diseases associated with complete ablation
of PD-1 or its ligands during LCMV infection (3, 4).
Immune suppression during later stages of persistent LCMV
infection has been attributed in part to the expansion of particular
innate immune suppressor cells, includingmyeloid tissue-derived
suppressor cells (5) and IL-10-expressing antigen-presenting cells
(6). Recent work by our group and others has suggested that nat-
ural killer (NK) cells can act at a very early stage of LCMV infec-
tion to curtail the development of a protective and potentially
pathogenic population of virus-specific T cells (7–9). It was pro-
posed that NK cells lysed CD4 (7) or CD8 (8) T cells during the
initial days of infection, when type I interferon (IFN) was preva-
lent and when the NK cells were thus cytolytically activated. This
resulted in a weaker antiviral T cell response that could not effect
viral clearance (7–9) or cause fatal immune pathology (7).
The potential link between type I IFN expression and NK cell-
mediated suppression of antiviral T cell responses (7, 8) is notable
given the relationship between an elevated type I IFN signature
and disease pathogenesis during chronic infections. In contrast to
rhesus macaques, which develop an AIDS-like syndrome after
simian immunodeficiency virus (SIV) infection, reduced IFN-as-
sociated inflammation is associated with modest disease in either
sooty mangabeys or African green monkeys (10, 11). Progression
of HIV infection has also been linked to both type I IFN (12) and
expression of particular NK cell receptors (13). Similarly, the ac-
tivation state of NK cells and type I IFN have been linked to both
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chronicity of HCV infection and refractoriness to antiviral ther-
apy (14, 15). Recently, two groups demonstrated that blockade of
type I IFN signaling during persistent LCMV infection in mice
could facilitate viral clearance (16, 17). If type I IFN contributes to
maintenance of persistent LCMV infection, and in consideration
of our previous findings that IFN activates NK cells in the LCMV
system (18), we reasoned that perhaps IFN-activated NK cells
continue to contribute to immune dysfunction and viral persis-
tence at later time points of infection.
MATERIALS AND METHODS
Mice.C57BL/6 mice were purchased from The Jackson Laboratories (Bar
Harbor, ME). IL-21 receptor knockout (IL-21R KO) mice on a C57BL/6
background were obtained fromWarren Leonard (19). Male mice at 6 to
12 weeks of age were routinely used for experiments. Mice were main-
tained under specific-pathogen-free conditions, and experiments were
conducted in compliance with guidelines approved by the Institutional
AnimalCare andUseCommittee of theUniversity ofMassachusettsMed-
ical School (UMMS).
Virus infections and in vivo cell depletion. The clone 13 variant
strain of LCMV was titrated by plaque assay on Vero cells after propaga-
tion in baby hamster kidney BHK21 cells (20). Mice were infected intra-
venously (i.v.) via the lateral tail vein with 2  105 to 5  105 (medium
dose), 2 106 (high dose), or 4 106 (very high dose) PFU of LCMV. To
selectively deplete NK cells, mice were injected intraperitoneally (i.p.)
once or twice with 25 g of anti-NK1.1 monoclonal antibody (MAb)
(PK136) or a control mouse IgG2a produced by Bio-X-Cell (West Leba-
non, NH), as previously described (7). Mice were depleted of CD4 T cells
by i.p. injection of 200 g of anti-CD4 (GK1.5), produced by Bio-X-Cell,
at days1 and1 of infection.
Peptides. T-cell epitopes encoded by LCMV included NP396–404 (FQ
PQNGQFI), GP33–41 (KAVYNFATC), GP61–80 (GLKGPDIYKGVYQFK
SVEFD), and GP276–286 (SGVENPGGYCL). Peptides were purchased
from 21st Century Biochemicals and purified by reverse-phase high-pres-
sure liquid chromatography (HPLC) to 90% purity.
Antibodies and fluorescence-activated cell sorter (FACS) analysis.
Fluorochrome-tagged antibodies were purchased from BD Biosciences
(San Jose, CA), eBioscience (San Diego, CA), and BioLegend (San Diego,
CA). Data collection was performed on an LSR II cytometer (BD Biosci-
ences) equipped with FACSDiva software, and data were analyzed using
FlowJo software (Tree Star, Ashland, OR).
Lymphocyte preparation and intracellular cytokine assay. Single-
cell leukocyte suspensions were prepared from spleens or peripheral
blood and plated at up to 2 106 cells per well in 96-well plates. Cells were
stimulated for 5 h at 37°C with either 1 M viral peptide or 2.5 g/ml
anti-CD3 antibody (BD Biosciences) in the presence of brefeldin A and
0.2 U/ml recombinant human IL-2 (rhIL-2). After stimulation, cells were
preincubated with a 1:200 dilution of Fc Block (2.4G2) (BD Biosciences)
in FACS buffer (Hanks balanced salt solution [HBSS], 2% fetal calf serum
[FCS], 0.1% NaN3) and stained for 20 min at 4°C with various combina-
tions of tagged antibodies. Cells were washed and then permeabilized
using BD Cytofix/Cytoperm solution prior to intracellular staining in BD
Permwash (BD Biosciences).
Statistical analysis. Results are routinely displayed as means stan-
dard errors of the means (SEM), with statistical differences between ex-
perimental groups determined using the Mann-Whitney U test, in which
a P value of0.05 was deemed significant. The limit of detection in viral
plaque assays was a log10 PFU value of 1 for the spleen and 2 for other
organs. Viral titers below the limit of detection were assigned a “less than”
value. Therefore, statistical analyses including viral infectivity determina-
tions below the level of detection will undervalue the true difference be-
tween groups. Data are presented as geometric mean titers, which are the
arithmetic means of the log10 viral titers. Graphs were produced and sta-
tistical analyses were performed using eitherMicrosoft Excel orGraphPad
Prism (San Diego, CA).
RESULTS
Timing of NK cell immunoregulatory activity. We previously
reported that whereas a high dose of LCMV clone 13 established a
persistent infection associated with clonal exhaustion of T cells, a
medium dose resulted in severe T cell-mediated immune pathol-
ogy (7). NK cell depletion prior to infection enhanced T cell re-
sponses at both doses, resulting in more rapid clearance of virus
and less pathology at the medium dose but, paradoxically, lethal
immune pathology at the higher dose, probably due to the failure
of the elevated T cell response to be exhausted. Notably, while
delayed depletion of NK cells on day 2 or 3 of medium-dose in-
fection could still enhance LCMV-specific CD8 T cell responses
measured on day 15 postinfection (p.i.), depletion at day 4 or 5 of
infection had little, if any, effect (7). Others have similarly ob-
served that NK cell suppression of LCMV-specific CD4 T cells
occurred prior to day 4 of infection (9).
Nonetheless, we show here that delayed depletion of NK cells
with anti-NK1.1 antibody on day 4 or 5 after infection with a
medium dose of LCMV clone 13 still resulted in a substantial
(120-fold) reduction in splenic viral load at day 15 of infection
compared to that in control mice treated with isotype control
antibody (Fig. 1A), despite the absence of an apparent effect on
LCMV NP396–404-specific CD8 T cell responses (Fig. 1B). In ad-
dition, NK cell depletion at any point during the first 5 days of
infection alleviated the severe weight loss normally caused by the
immunopathological T cell response to medium-dose LCMV
clone 13 infection. This reduced pathology was most pronounced
in mice depleted of NK cells during the initial 2 days of infection
but was still apparent in those depleted at day 3, 4, or 5 of infection
(Fig. 1C). Taken together, these experiments using amediumdose
of virus demonstrated that NK cells may continue to play an ad-
ditional yet less prominent role in viral pathogenesis beyond the
first few days of infection.
Delayed NK cell depletion improves control of persistent
LCMV infection. The fact that NK cells continued to impair viral
control at later times of medium-dose LCMV clone 13 infection
suggested a possible role for NK cells in the maintenance of viral
persistence during infection with a high dose of virus, which nor-
mally causes a persistent infection due to substantial T cell clonal
exhaustion. In order to assess whether NK cells supported sus-
tained virus replication during persistence, we first attempted to
deplete NK cells at a time point of high-dose LCMV clone 13
infection (day 10) just subsequent to the clonal exhaustion and
depletion of virus-specific T cells (21, 22). Remarkably, adminis-
tration of anti-NK1.1 antibody at days 10 and 13 of high-dose
infection caused a 10-fold reduction in levels of viremia at day 15
p.i. relative to those in isotype control-treatedmice (Fig. 2A). This
enhanced control of virus replicationwasmaintained at least 10 to
20 days after the last administration of NK cell-depleting anti-
body. Thus, NK cells continue to suppress viral control late in
high-dose LCMV clone 13 infection, and depletion of NK cells has
a therapeutic benefit.
Late NK cell depletion is less pathogenic than early NK cell
depletion. Of particular concern to the concept of therapeutic
NK cell depletion is our previous observation that the early
depletion of NK cells prior to high-dose LCMV clone 13 infec-
tion resulted in severe immunopathology and heightened mor-
tality during the second week of infection (7). In contrast, ther-
apeutic depletion of NK cells at days 10 and 13 of high-dose
Waggoner et al.
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LCMV clone 13 infection did not result in either death or in-
creased weight loss. In fact, NK cell-depleted mice had gained
more weight than control mice 3 to 4 weeks after anti-NK1.1
antibodies were administered (Fig. 2B).
Therapeutic removal of NK cells enhances control of estab-
lished persistent infection. Three weeks after infection with a
high dose of LCMV clone 13, viral persistence is firmly estab-
lished, coincident with virtually undetectable CD8 T cell re-
sponses to the Db-restricted NP396–404 epitope of LCMV and
highly dysfunctional CD8 T cell responses to other viral epitopes
in regard to cytokine production (21, 22). Therefore, we sought to
determine whether NK cell depletion at even later time points of
established persistent infection could also enhance viral control.
At day 21 of high-dose LCMV clone 13 infection, mice were ad-
ministered a single dose of anti-NK1.1 antibody or an isotype
control i.p. The efficacy of depletion was evident in the reduced
number of splenic CD3 NKp46 NK cells 6 days after the ad-
ministration of NK cell-depleting antibody on day 20 p.i. (control
group [n 9], 2.3 105 0.38 105 NK cells; and 	NK group
[n 8], 0.68 105 0.093 105 NK cells; P 0.0016) and 14
days after anti-NK1.1 therapy on day 30 p.i. (control group [n
5], 1.0  105  0.14  105 NK cells; and 	NK group [n  5],
0.27 105 0.015 105 NK cells; P 0.00086). Viral load was
reduced 14- and 16-fold in the spleen and liver, respectively, of
therapeutically NK cell-depleted mice relative to isotype-treated
mice 10 to 12 days after administration of a single inoculation of
depleting antibody (Fig. 2C). Furthermore, single injections of
NK cell-depleting antibodies could be administered at very late
time points, i.e., 28 to 31 days after infection, and still cause 11- to
29-fold reductions of viral loads in the spleen and serum 2 weeks
after therapy onset relative to those in control mice (Fig. 2D).
Notably, viral titers were also reduced 11-fold in the kidneys, a
tissue where LCMV clone 13 usually persists indefinitely (23).
Control of LCMV replication is predominately mediated by
class I major histocompatibility complex (MHC)-restricted vi-
rus-specific CD8 T cells (24). In line with the reduced levels of
replicating virus after NK cell depletion therapy, we observed
an increase in the frequency of Db-restricted LCMV GP33–41-
specific CD8 T cells in the blood and spleen of therapeutically
NK cell-depleted mice relative to isotype-treated mice at days
41 to 44 of infection, 12 to 14 days after the onset of therapy
(Fig. 3A and B). The responses of CD4 T cells specific for the
I-Ab-restricted LCMV GP61–81 epitope were marginally in-
creased after therapeutic NK cell depletion, but the total num-
ber of IFN-
-producing CD4 T cells in response to anti-CD3
stimulation was more dramatically enhanced (Fig. 3C). To-
gether, these studies suggest that NK cells continue to suppress
LCMV-specific T cell responses and viral control at very late
time points of persistent infection.
Effect of NK cell depletion is sensitive to virus dose and de-
gree of exhaustion. In contrast to our findings, a recent report
suggested that depletion of NK cells at day 4, 7, 11, or 14 of
high-dose LCMV clone 13 infection had no measurable effect
on virus-specific T cell numbers as measured by cytokine pro-
duction (9). In total, we detectedmeasurable increases in virus-
specific T cell responses and reduced viral loads as a result of
therapeutic NK cell depletion in 10 independent experiments.
Nevertheless, in three experiments, we observed that the effects
of NK cell depletion at late time points of infection were min-
imal or statistically insignificant with regard to either viral bur-
FIG 1 Timing of NK cell immunoregulatory activities during pathogenic me-
dium-dose infection. C57BL/6 mice (n  3/group) were treated with either
NK cell-depleting anti-NK1.1 antibody or a nondepleting isotype control at
various time points relative to i.v. inoculation with a medium dose (2  105
PFU) of LCMV clone 13. (A) At day 15 p.i., viral titers in the spleen were
determined. Values below the lower limit of detection (log10 PFU 1.0; dotted
line) were assigned a “less than” value. *, P 0.05 versus nondepleted group.
(B) Numbers of splenic IFN-
 TNF LCMV NP396–404-specific CD8 T cells
were determined at day 15 p.i. by intracellular cytokine staining. *, P  0.05
versus nondepleted group. TNF, tumor necrosis factor. (C) Body weight was
measured daily, and three patterns of weight loss were observed. The mean %
of initial body weight was graphed as a function of time for nondepleted mice
(black line; n 3) and for pooled (phenotypically) groups of mice depleted at
very early (day 1 [D1], D1, or D2) (red line; n  8) and later (D3,
D4, or D5) (blue line; n  9) times of infection. **, P  0.01 versus
nondepleted group; #, P 0.05 versusD3 toD5 group; ##, P 0.01 versus
D3 to D5 group. Data are presented as means SEM and are representa-
tive of two independent experiments.
Viral Persistence and Therapeutic NK Cell Depletion
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den or virus-specific T cell responses (data not shown). In these
cases, virus-specific cytokine-producing T cell responses ap-
peared weaker than those in typical high-dose LCMV clone
13-infected mice at similar time points. For example, the fre-
quency of splenic LCMV-specific IFN-
CD8 T cells on day 40
p.i. was higher in a nondepleted group of control mice (2.2 
104 0.58 104 GP33–41-specific IFN-

CD8 T cells) from an
experiment where NK cell depletion enhanced viral control
than in the control group (1.3  104  0.46  104 GP33–41-
specific IFN-
 CD8 T cells) from an experiment where there
was no measurable benefit of NK cell depletion.
To determine whether experimental variation in viral load
could affect the efficacy of NK cell depletion-based therapy, we
first examined whether the inoculum dose could be increased
to overcome the effects of NK cell depletion. In agreement with
our previous work (7), intravenous infection with a normally
nonlethal high dose (2  106 PFU) of LCMV clone 13 caused
substantial weight loss that was more severe if NK cells were
depleted at the time of infection, resulting in 66% mortality
(Fig. 4A). We show here that increasing the original virus in-
oculum further, to 4 106 PFU, overcame the effects of NK cell
depletion, resulting in weight loss that was comparable to that
of isotype-treated mice, as well as 100% survival (Fig. 4B).
These features were likely related to the increased degree of
FIG 2 Therapeutic depletion of NK cells enhances control of persistent LCMV infection. Groups of C57BL/6mice were inoculated i.v. with a high dose (2 106
PFU) of LCMV clone 13. (A and B) At days 10 and 13 p.i., mice were either treated with an isotype control antibody (n 8) or depleted of NK cells (n 9). (A)
Viral titers in serum. (B) Body weights (n 6/group) relative to weights prior to NK cell depletion on day 10 p.i. (C and D) Other groups of mice were treated
with isotype control antibody or given a single injection of anti-NK1.1 antibody on days 20 and 21 (C) or days 28 to 31 (D) of infection. Viral titers in various
tissues of isotype control (n 9 or 10)- or anti-NK1.1 (n 10)-treated mice were determined 10 to 13 (C) or 12 to 14 (D) days after NK cell depletion. Values
below the limit of detection for the spleen (log10 PFU 1) and other tissues (log10 PFU 2) were assigned a “less than” value. Data in panels A, C, and D were
pooled from two independent experiments. Data in panel B are representative of two similar experiments.
FIG 3 Therapeutic depletion of NK cells augments virus-specific T cell responses. Groups of C57BL/6 mice were inoculated i.v. with a high dose (2 106 PFU)
of LCMV clone 13. At days 28 to 31 of infection, mice were either treated with isotype control antibody (n 8) or depleted of NK cells (n 9). Proportions (A)
and numbers (B) of LCMVGP33–41-specific CD8 T cells in the blood and spleen were determined by intracellular cytokine staining after ex vivo stimulation with
peptide or anti-CD3 antibody. (C) Numbers of IFN-
 CD4 T cells (n 5/group) in the spleen. Data were pooled from two independent experiments.
Waggoner et al.
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functional exhaustion (data not shown) of virus-specific CD8
T cells at the higher inocula.
Based on these findings, we compared the efficacies of NK cell
depletion therapy during persistent infection with a high (2 106
PFU) or very high (4 106 PFU)dose of LCMVclone 13.Whereas
depletion of NK cells at day 10 of high-dose infection resulted in
reduced viral burdens in the serum (Fig. 4C) and spleen (Fig. 4D)
at day 31 p.i., the same regimen given after very-high-dose infec-
tion had little effect on viral control. Notably, the ability of NK cell
depletion to effect a reduction in viremia was inversely correlated
with the levels of viremia at the time of NK cell depletion in a
group of mice infected with 2 106 PFU of virus (Fig. 4E). Thus,
the value of therapeutic depletion ofNK cells in enhancing control
of persistent virus infection may depend on viral burden and the
extent of immune exhaustion.
Potential role for CD4 T cells in NK cell depletion therapy.
Enhancement of LCMV-specific CD8 T cell responses and immu-
nopathology after high-dose LCMV clone 13 infection in the ab-
sence of NK cells was shown by us to be dependent on CD4 T cells
(7). To examine whether CD4 T cells were required for therapeu-
tic NK cell depletion-mediated enhancement of LCMV-specific
CD8T cell responses and viral control, mice were depleted of CD4
T cells by use of an antibody to CD4 and then given high-dose
LCMV clone 13. At days 26 to 29 p.i., mice were given either
FIG 4 Effect of NK cell depletion is sensitive to size of LCMV inoculum. C57BL/6 mice (n  3 or 4/group) were depleted of NK cells or treated with isotype
control antibody 1 day prior to infection with a high (2 106 PFU) (A) or very high (4 106 PFU) (B) dose of LCMV clone 13 i.v. Body weight and survival were
monitored for 11 days. (C and D) Mice (n 5/group) were infected for 10 days with a high (2 106 PFU) or very high (4 106 PFU) dose of LCMV clone 13
prior to isotype control treatment or administration of anti-NK1.1 antibody. At day 31 p.i., 21 days after treatment, viral titers in the sera (C) and spleens (D) of
these mice were determined. (E) For a group of mice infected with the high (2 106 PFU) dose of LCMV clone 13, viral titers in sera just prior to depletion of
NK cells (day 10) were plotted against the % reduction in viral titers in sera 21 days later (endpoint viral titer/initial viral titer 100% reduction), revealing
an inverse relationship between these parameters.
Viral Persistence and Therapeutic NK Cell Depletion
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anti-NK1.1 or an isotope control i.p. In contrast to NK cell deple-
tion in CD4-replete mice, NK cell depletion did not enhance
LCMV-specific CD8 T cell responses (Fig. 5A) or viral control
(Fig. 5B) in mice infected with a high dose of LCMV clone 13 in
the absence of CD4 T cells.
DISCUSSION
A number of studies have now demonstrated that NK cells at a
very early stage of infection, when they are highly activated by
high levels of IFN and other cytokines, can suppress antiviral T
cell responses (reviewed in reference 25). Here we describe a
role for NK cells in continuing to impair virus-specific T cell
responses and viral control well after viral persistence has been
established. In fact, depletion of NK cells in mice persistently
infected with LCMV represents a viable therapeutic approach
to reinvigorate virus-specific T cell responses and reduce viral
burdens. In contrast to the fatal disease associated with deple-
tion of NK cells at the onset of high-dose LCMV clone 13
infection (7), delayed depletion of NK cells during established
persistence did not result in exacerbated morbidity and mor-
tality. This suggests that NK cell depletion therapymay be a safe
approach to increase immune function. This parallels recently
published studies showing that early blockade of type 1 IFN
activity enhanced viral loads but blockade of IFN activity later
on, during persistence, reduced viral loads (16, 17).
Whereas removal of immunoregulatory NK cells seemed to
be a safe and effective strategy to enhance immunity during
persistent infection, the success of this approach was depen-
dent upon the severity of immune dysfunction. Functional ex-
haustion of virus-specific CD8 T cells during LCMV infection
is a consequence of persistently high levels of viral antigen (26,
27). CD4 T cells can act to sustain virus-specific CD8 T cell
function under conditions of high virus load (28), and this
activity involves production of the cytokine IL-21 (29–31). In
this study, immune dysfunction was amplified by increasing
the viral burden via a very high inoculum of virus or through
elimination of CD4 T cells. Under these conditions, NK cell
depletion by itself was no longer an effective means of enhanc-
ing immune-mediated control of LCMV infection. Further-
more, our preliminary data indicate that NK cell depletion of
IL-21 receptor-deficient mice infected with a high dose of
LCMV clone 13 also did not enhance LCMV-specific CD8 T
cell responses or reduce the viral burden in the spleen (data not
shown). Thus, CD4 T cells and IL-21 are important compo-
nents of the ability of NK cell depletion therapy to enhance
control of a persistent virus infection.
In the current study, a relationship was evident between the
size of the viral inoculum and the ability of NK cell depletion to
enhance immune-mediated control of persistent LCMV infec-
tion. Preliminary data indicated that administration of a very
high dose of virus was associated with a slightly more pro-
nounced exhaustion phenotype of activated CD8 T cells, i.e.,
reduced expression of KLRG1 (32), than that observed after
infection with the “normal” high dose of virus (data not
shown). A greater degree of exhaustion may have contributed
to the negligible immune-enhancing efficacy of NK cell deple-
tion during very-high-dose LCMV infections and could poten-
tially account for differences in the efficacy of this therapeutic
regimen among individual mice infected with the normal high
dose of LCMV. In this regard, the level of viremia at the onset of
NK cell depletion therapy was inversely correlated with the
effectiveness of this regimen in enhancing viral control. Al-
though more substantial parallels must be drawn between im-
mune status and the amenability of individual of mice to this
therapy, these findings provide a basis from which to explore
parameters that may be clinically relevant to the determination
of when NK cell depletion would be an appropriate treatment
for chronic viral infection.
Recent studies from several groups have highlighted the exis-
tence of long-lived NK cells that display characteristics of immu-
nological memory, including more robust responsiveness upon
secondary stimulation (33). Such “memory” NK cells have been
postulated to contribute to immunity in the context of cytomeg-
alovirus infections in both mice (34) and humans (35). The exis-
tence of amemory-like population ofNK cells inmice persistently
infectedwith LCMV is not known, and if they are present, itmight
be difficult to distinguish them from activated NK cells in this
cytokine-rich environment. Furthermore, our NK cell depletion
strategy was sufficient to eliminate NK cells in the liver, which is a
reservoir for putative NKmemory cells, so if they were there, they
should still have been depleted by our approach.
NK cell depletion during persistent LCMV infection likely en-
hances the proliferation or antiviral activity of a population of
partially exhausted virus-specific T cells. Our data are consistent
with but do not fully prove the hypothesis that the NK cell inhibi-
FIG 5 CD4 T cells are required for efficacy of NK cell depletion therapy.
C57BL/6 mice were either depleted of CD4 T cells (n  10/group) or treated
with isotype control antibody (n 5/group) at days1 and1 of high-dose
LCMV clone 13 infection. At days 26 to 29 of infection, groups of mice were
either treated with isotype control antibody or depleted of NK cells. LCMV-
specific CD8 T cell responses (A) and viral titers (B) were measured in the
spleen. These results were pooled from two independent experiments.
Waggoner et al.
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tion of T cell functionality is mediated through suppression of
CD4 T cell-derived IL-21. Alternatively, CD4 T cells and IL-21
may act separately from NK cells, though we have clearly estab-
lished that NK cell-mediated lysis of CD4 T cells controls CD8
responses earlier in infection (7). A separate study recently iden-
tified a similar suppressive activity for NK cells at late stages of
persistent retrovirus infection (36). Thus, depletion of NK cells
may augment immune-mediated control of a persistent virus in-
fection, with an apparent lack of detrimental health consequences
associated with such depletion. This suggests that NK cell deple-
tion or a regimen to inhibit NK cell function could be combined
with other therapeutic strategies, including PD-1 or IL-10 block-
ade (2, 3), which has been shown to be partially effective at clear-
ing persistent LCMV infection.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health (NIH) training
grant AI07349 (S.N.W.), by a New Scholar Award from The EllisonMed-
ical Foundation (S.N.W.), and by research grants AI-17672, AI-081675,
and CA34461 (R.M.W.).
We thank Carey Zammitti, Steven Hatfield, and Laurie Kenney for
providing technical and administrative support; Liisa Selin and Eva
Szomolanyi-Tsuda for insightful discussions; and Heather Ducharme as
well as AmandaCyr formouse husbandry.We thankWarren Leonard and
Susan Swain for IL-21R KO mice.
The views expressed are those of the authors and do not necessarily
express the views of the NIH.
The authors declare that there are no financial conflicts of interest.
REFERENCES
1. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S,
von Herrath MG. 2006. Resolution of a chronic viral infection after
interleukin-10 receptor blockade. J. Exp. Med. 203:2461–2472. http://dx
.doi.org/10.1084/jem.20061462.
2. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone
MB. 2006. Interleukin-10 determines viral clearance or persistence in vivo.
Nat. Med. 12:1301–1309. http://dx.doi.org/10.1038/nm1492.
3. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH,
Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T
cells during chronic viral infection. Nature 439:682–687. http://dx.doi
.org/10.1038/nature04444.
4. Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel
J, Wagner CA, Loffing-Cueni D, Kurrer M, Ludewig B, Oxenius A.
2012. Programmed death 1 protects from fatal circulatory failure during
systemic virus infection of mice. J. Exp. Med. 209:2485–2499. http://dx
.doi.org/10.1084/jem.20121015.
5. Norris BA, Uebelhoer LS, Nakaya HI, Price AA, Grakoui A, Pulendran
B. 2013. Chronic but not acute virus infection induces sustained expan-
sion of myeloid suppressor cell numbers that inhibit viral-specific T cell
immunity. Immunity 38:309–321. http://dx.doi.org/10.1016/j.immuni
.2012.10.022.
6. Wilson EB, Kidani Y, Elsaesser H, Barnard J, Raff L, Karp CL, Bensinger
S, Brooks DG. 2012. Emergence of distinct multiarmed immunoregulatory
antigen-presenting cells during persistent viral infection. Cell Host Microbe
11:481–491. http://dx.doi.org/10.1016/j.chom.2012.03.009.
7. Waggoner SN, Cornberg M, Selin LK, Welsh RM. 2012. Natural killer
cells act as rheostats modulating antiviral T cells. Nature 481:394–398.
http://dx.doi.org/10.1038/nature10624.
8. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, Elford AR,
Dhanji S, Shaabani N, Tran CW, Dissanayake D, Rahbar R, Ghazarian
M, Brustle A, Fine J, Chen P, Weaver CT, Klose C, Diefenbach A,
Haussinger D, Carlyle JR, Kaech SM, Mak TW, Ohashi PS. 2012.
Natural killer cell activation enhances immune pathology and promotes
chronic infection by limiting CD8 T-cell immunity. Proc. Natl. Acad.
Sci. U. S. A. 109:1210–1215. http://dx.doi.org/10.1073/pnas.1118834109.
9. Cook KD, Whitmire JK. 2013. The depletion of NK cells prevents T cell
exhaustion to efficiently control disseminating virus infection. J. Immu-
nol. 190:641–649. http://dx.doi.org/10.4049/jimmunol.1202448.
10. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G,
Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P,
Barre-Sinoussi F, Benecke A, Muller-Trutwin MC. 2009. Nonpatho-
genic SIV infection of African greenmonkeys induces a strong but rapidly
controlled type I IFN response. J. Clin. Invest. 119:3544–3555. http://dx
.doi.org/10.1172/JCI40093.
11. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N,
Sidahmed A, Smith AJ, Cramer EM, Zeng M, Masopust D, Carlis JV,
Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG,
Staprans SI, Silvestri G, Haase AT, Kelvin DJ. 2009. Global genomic
analysis reveals rapid control of a robust innate response in SIV-infected
sooty mangabeys. J. Clin. Invest. 119:3556–3572. http://dx.doi.org/10
.1172/JCI40115.
12. Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Kruhlak MJ, Anderson
SA, Dolan MJ, Dy M, Andersson J, Shearer GM. 2006. Differential
expression of IFN-alpha andTRAIL/DR5 in lymphoid tissue of progressor
versus nonprogressor HIV-1-infected patients. Proc. Natl. Acad. Sci.
U. S. A. 103:7000–7005. http://dx.doi.org/10.1073/pnas.0600363103.
13. Bashirova AA, Thomas R, Carrington M. 2011. HLA/KIR restraint of
HIV: surviving the fittest. Annu. Rev. Immunol. 29:295–317. http://dx.doi
.org/10.1146/annurev-immunol-031210-101332.
14. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J,
Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM,
Alexander GJ, Cramp ME, O’Brien SJ, Rosenberg WM, Thomas DL,
Carrington M. 2004. HLA and NK cell inhibitory receptor genes in re-
solving hepatitis C virus infection. Science 305:872–874. http://dx.doi.org
/10.1126/science.1097670.
15. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M,
Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B. 2012. Early changes
in interferon signaling define natural killer cell response and refractoriness
to interferon-based therapy of hepatitis C patients. Hepatology 55:39–48.
http://dx.doi.org/10.1002/hep.24628.
16. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M,
Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV
infection is controlled by blockade of type I interferon signaling. Science
340:207–211. http://dx.doi.org/10.1126/science.1235214.
17. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G,
Aronow BJ, Karp CL, Brooks DG. 2013. Blockade of chronic type I
interferon signaling to control persistent LCMV infection. Science 340:
202–207. http://dx.doi.org/10.1126/science.1235208.
18. Welsh RM, Jr. 1978. Cytotoxic cells induced during lymphocytic chorio-
meningitis virus infection of mice. I. Characterization of natural killer cell
induction. J. Exp. Med. 148:163–181.
19. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC, 3rd,
Liu C, Schwartzberg PL, Leonard WJ. 2002. A critical role for IL-21 in
regulating immunoglobulin production. Science 298:1630–1634. http:
//dx.doi.org/10.1126/science.1077002.
20. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MB. 1984. Selection
of genetic variants of lymphocytic choriomeningitis virus in spleens of
persistently infected mice. Role in suppression of cytotoxic T lymphocyte
response and viral persistence. J. Exp. Med. 160:521–540.
21. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R.
2003. Viral persistence alters CD8 T-cell immunodominance and tissue dis-
tribution and results in distinct stages of functional impairment. J. Virol. 77:
4911–4927. http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003.
22. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M,
Altman JD, Ahmed R. 1998. Viral immune evasion due to persistence of
activated T cells without effector function. J. Exp. Med. 188:2205–2213.
http://dx.doi.org/10.1084/jem.188.12.2205.
23. Ahmed R, Jamieson BD, Porter DD. 1987. Immune therapy of a persis-
tent and disseminated viral infection. J. Virol. 61:3920–3929.
24. Zinkernagel RM, Welsh RM. 1976. H-2 compatibility requirement for
virus-specific T cell-mediated effector functions in vivo. I. Specificity
of T cells conferring antiviral protection against lymphocytic chorio-
meningitis virus is associated with H-2K and H-2D. J. Immunol. 117:
1495–1502.
25. Welsh RM, Waggoner SN. 2013. NK cells controlling virus-specific T
cells: Rheostats for acute vs. persistent infections. Virology 435:37–45.
http://dx.doi.org/10.1016/j.virol.2012.10.005.
26. Mueller SN, Ahmed R. 2009. High antigen levels are the cause of T cell
exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U. S. A.
106:8623–8628. http://dx.doi.org/10.1073/pnas.0809818106.
Viral Persistence and Therapeutic NK Cell Depletion
February 2014 Volume 88 Number 4 jvi.asm.org 1959
 o
n
 N
ovem
ber 25, 2015 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
27. Fuller MJ, Zajac AJ. 2003. Ablation of CD8 and CD4 T cell responses by
high viral loads. J. Immunol. 170:477–486.
28. Matloubian M, Concepcion RJ, Ahmed R. 1994. CD4 T cells are
required to sustain CD8 cytotoxic T-cell responses during chronic viral
infection. J. Virol. 68:8056–8063.
29. Elsaesser H, Sauer K, Brooks DG. 2009. IL-21 is required to control
chronic viral infection. Science 324:1569–1572. http://dx.doi.org/10.1126
/science.1174182.
30. Yi JS, Du M, Zajac AJ. 2009. A vital role for interleukin-21 in the control
of a chronic viral infection. Science 324:1572–1576. http://dx.doi.org/10
.1126/science.1175194.
31. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J,
Marsland BJ, Oxenius A, Kopf M. 2009. IL-21R on T cells is critical for
sustained functionality and control of chronic viral infection. Science 324:
1576–1580. http://dx.doi.org/10.1126/science.1172815.
32. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subra-
maniam S, Blattman JN, Barber DL, Ahmed R. 2007. Molecular signa-
ture of CD8 T cell exhaustion during chronic viral infection. Immunity
27:670–684. http://dx.doi.org/10.1016/j.immuni.2007.09.006.
33. Min-Oo G, Kamimura Y, Hendricks DW, Nabekura T, Lanier LL.
2013. Natural killer cells: walking three paths down memory lane.
Trends Immunol. 34:251–258. http://dx.doi.org/10.1016/j.it.2013.02
.005.
34. Sun JC, Beilke JN, Lanier LL. 2009. Adaptive immune features of natural
killer cells. Nature 457:557–561. http://dx.doi.org/10.1038/nature07665.
35. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York
VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL.
2011. Expansion of a unique CD57NKG2Chi natural killer cell subset
during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci.
U. S. A. 108:14725–14732. http://dx.doi.org/10.1073/pnas.1110900108.
36. Littwitz E, Francois S, Dittmer U, Gibbert K. 2013. Distinct roles of NK
cells in viral immunity during different phases of acute Friend retrovirus
infection. Retrovirology 10:127. http://dx.doi.org/10.1186/1742-4690-10
-127.
Waggoner et al.
1960 jvi.asm.org Journal of Virology
 o
n
 N
ovem
ber 25, 2015 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
